Trial Profile
A multi-center, randomized, proof-of-concept, parallel control study with Remind Cap in patients with essential hypertension and newly treated with valsartan+/-hydrochlorothiazide (HCTZ)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2007
Price :
$35
*
At a glance
- Drugs Valsartan (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Jul 2007 New trial record.